Share on StockTwits

BioDelivery Sciences International (NASDAQ:BDSI) EVP Andrew L. Finn sold 90,000 shares of the stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $15.00, for a total value of $1,350,000.00. Following the completion of the transaction, the executive vice president now directly owns 571,064 shares of the company’s stock, valued at approximately $8,565,960. The transaction was disclosed in a filing with the SEC, which is available at this link.

Several analysts have recently commented on the stock. Analysts at Roth Capital raised their price target on shares of BioDelivery Sciences International to $20.00 in a research note on Friday, August 8th. Separately, analysts at Ladenburg Thalmann raised their price target on shares of BioDelivery Sciences International to $21.00 in a research note on Wednesday, July 9th. They now have a “buy” rating on the stock. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $20.50.

Shares of BioDelivery Sciences International (NASDAQ:BDSI) traded up 2.11% during mid-day trading on Friday, hitting $16.00. The stock had a trading volume of 757,259 shares. BioDelivery Sciences International has a one year low of $4.16 and a one year high of $16.15. The stock’s 50-day moving average is $13.40 and its 200-day moving average is $10.51. The company’s market cap is $788.8 million.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its earnings results on Friday, August 15th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.07. On average, analysts predict that BioDelivery Sciences International will post $-0.67 earnings per share for the current fiscal year.

BioDelivery Sciences International, Inc (NASDAQ:BDSI) is a specialty pharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.